Please login to the form below

Not currently logged in
Email:
Password:

generics

This page shows the latest generics news and features for those working in and with pharma, biotech and healthcare.

With Spiriva under pressure, Boehringer moves to bolster pipeline

With Spiriva under pressure, Boehringer moves to bolster pipeline

Spiriva is now off-patent in most markets but has been buffered from the steep declines that generally follow from generic competition because of the complexities of showing equivalence to the ... delivery device – a factor that also held up generics

Latest news

  • Brexit causing ‘significant’ generic drug shortages Brexit causing ‘significant’ generic drug shortages

    Community pharmacies are reporting increasing problems sourcing some generic medicines for their patients,” said Simon Dukes, the chief executive of PSNC. ... However Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA

  • Tit for tat as PBMs blame pharma for high drug prices Tit for tat as PBMs blame pharma for high drug prices

    The PBMs also cited “pay for delay” and other anti-competitive practices in the pharma industry such as withholding samples from generic manufacturers and tweaking formulations to extend patent life among

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    The HIV therapy market is also likely to be affected by the arrival of generic versions of lamivudine. ... If the cost of prescribing Tivicay (dolutegravir) plus generic lamivudine is substantially lower than the cost of Dovato, it’s possible

  • Gilead and Galapagos close in on filing for Xeljanz rival Gilead and Galapagos close in on filing for Xeljanz rival

    In FINCH 1, selective JAK1 inhibitor filgotinib was compared to AbbVie’s $18bn-a-year TNF antibody Humira (adalimumab) or placebo – given on top of generic disease-modifying antirheumatic drug (DMARD)

  • Daiichi Sankyo starts mirogabalin trial in spinal injury pain Daiichi Sankyo starts mirogabalin trial in spinal injury pain

    rival to Pfizer’s big-selling Lyrica (pregabalin) brand which brought in $4.7bn last year despite generic competition in some markets. ... The challenge for Daiichi Sankyo with mirogabalin will be positioning it as a realistic alternative to pregabalin

More from news
Approximately 77 fully matching, plus 1,708 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    J&J needs the drug to hit the ground running because its existing prostate cancer blockbuster Zytiga is faceing generic competition in the US, which accounts for around half of the

  • Why precision medicine demands precision engagement Why precision medicine demands precision engagement

    Every interaction needs to be targeted specifically at the healthcare professional’s needs and interests in order to be valuable – generic information is no longer sufficient.

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... branded and generic competitors by being active in both sides of the market.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    These new products will help offset the patent expiry of one of Pfizer’s biggest products, pain treatment Lyrica, which will see generics arrive at the end of December. ... generic medicines.

More from intelligence
Approximately 6 fully matching, plus 156 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • Random42 Attending Jefferies 2018 London Healthcare Conference

    The event will feature leading public and private companies from the pharmaceutical, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from all over the world.

  • What does a future-proof rep look like?

    Gone are the days of generic data presentations - these brand value propositions should only form one part of a much richer process.

  • OPEN Access Consulting

    What OPEN Access Consulting do:. We have unrivalled experience in the delivery of market access programmes from early phase insights to generic/biosimilar strategies. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar

  • Rainmaker Healthcare Communications

    Our experience across pharmaceuticals, generics, OTC, medical devices and health-tech, has given us an unrivalled knowledge and long-term clients on 3 continents.

  • What to look for in a medical market research company

    Some agencies are generalists, carrying out research in a wide range of product areas; that’s fine if you’re undertaking generic consumer research and want to run a large online

More from PMHub
Approximately 0 fully matching, plus 49 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics